Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.12
(-1.63%)
SEK 0.12
(-1.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -41.8 Million SEK | -4033.33% |
| 2022 | 2.4 Million SEK | 41.18% |
| 2021 | 1.7 Million SEK | 1800.0% |
| 2020 | -100 Thousand SEK | -125.0% |
| 2019 | 400 Thousand SEK | -42.86% |
| 2018 | 700 Thousand SEK | 101.21% |
| 2017 | -58.04 Million SEK | -1547.29% |
| 2016 | 4.01 Million SEK | 108.91% |
| 2015 | -44.99 Million SEK | -112.94% |
| 2014 | -21.12 Million SEK | -24.7% |
| 2013 | -16.94 Million SEK | -46.5% |
| 2012 | -11.56 Million SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -21.2 Million SEK | -3.41% |
| 2024 Q3 | 2.2 Million SEK | 110.38% |
| 2024 Q1 | -20.5 Million SEK | -2.5% |
| 2023 Q3 | 900 Thousand SEK | 0.0% |
| 2023 FY | -94.4 Million SEK | -4033.33% |
| 2023 Q2 | - SEK | -100.0% |
| 2023 Q4 | -20 Million SEK | -2322.22% |
| 2023 Q1 | 500 Thousand SEK | -28.57% |
| 2022 Q2 | 100 Thousand SEK | 150.0% |
| 2022 FY | 2.4 Million SEK | 41.18% |
| 2022 Q1 | -200 Thousand SEK | -133.33% |
| 2022 Q4 | 700 Thousand SEK | 40.0% |
| 2022 Q3 | 500 Thousand SEK | 400.0% |
| 2021 Q3 | 300 Thousand SEK | -50.0% |
| 2021 FY | 1.7 Million SEK | 1800.0% |
| 2021 Q2 | 600 Thousand SEK | 500.0% |
| 2021 Q4 | 600 Thousand SEK | 100.0% |
| 2021 Q1 | 100 Thousand SEK | 0.0% |
| 2020 FY | -100 Thousand SEK | -125.0% |
| 2020 Q3 | 100 Thousand SEK | 200.0% |
| 2020 Q4 | - SEK | -100.0% |
| 2020 Q2 | -100 Thousand SEK | 0.0% |
| 2020 Q1 | - SEK | -100.0% |
| 2019 FY | 400 Thousand SEK | -42.86% |
| 2019 Q1 | 200 Thousand SEK | 0.0% |
| 2019 Q2 | -200 Thousand SEK | -200.0% |
| 2019 Q3 | 200 Thousand SEK | 200.0% |
| 2019 Q4 | 200 Thousand SEK | 0.0% |
| 2018 Q4 | 200 Thousand SEK | 0.0% |
| 2018 FY | 700 Thousand SEK | 101.21% |
| 2018 Q2 | - SEK | -100.0% |
| 2018 Q3 | 200 Thousand SEK | 0.0% |
| 2018 Q1 | 300 Thousand SEK | 104.6% |
| 2017 Q3 | -79.71 Thousand SEK | -106.9% |
| 2017 Q2 | 1.15 Million SEK | 23.54% |
| 2017 Q4 | -6.51 Million SEK | -8073.91% |
| 2017 Q1 | 935.82 Thousand SEK | 110.32% |
| 2017 FY | -58.04 Million SEK | -1547.29% |
| 2016 Q4 | -9.07 Million SEK | -29.67% |
| 2016 Q3 | -6.99 Million SEK | -922.33% |
| 2016 Q1 | 977.12 Thousand SEK | 118.63% |
| 2016 Q2 | 850.67 Thousand SEK | -12.94% |
| 2016 FY | 4.01 Million SEK | 108.91% |
| 2015 Q3 | -4.22 Million SEK | 27.16% |
| 2015 Q1 | -5.3 Million SEK | -20.5% |
| 2015 Q4 | -5.24 Million SEK | -24.23% |
| 2015 FY | -44.99 Million SEK | -112.94% |
| 2015 Q2 | -5.79 Million SEK | -9.2% |
| 2014 Q3 | -3.14 Million SEK | 54.46% |
| 2014 FY | -21.12 Million SEK | -24.7% |
| 2014 Q2 | -6.9 Million SEK | -3.55% |
| 2014 Q1 | -6.67 Million SEK | -23.92% |
| 2014 Q4 | -4.4 Million SEK | -40.0% |
| 2013 Q1 | -4.01 Million SEK | 65.27% |
| 2013 Q2 | -4.46 Million SEK | -11.12% |
| 2013 FY | -16.94 Million SEK | -46.5% |
| 2013 Q4 | -5.38 Million SEK | -74.8% |
| 2013 Q3 | -3.07 Million SEK | 31.01% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q4 | -11.56 Million SEK | 0.0% |
| 2012 FY | -11.56 Million SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q2 | 486.03 Thousand SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 Q1 | - SEK | 0.0% |
| 2010 Q3 | - SEK | -100.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 889.126% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 113.906% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 113.906% |
| Arcoma AB | 11.07 Million SEK | 477.563% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 129.861% |
| BICO Group AB (publ) | 1.83 Billion SEK | 102.283% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 116.739% |
| CellaVision AB (publ) | 463.04 Million SEK | 109.027% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 1494.728% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | -47.11% |
| C-Rad AB (publ) | 66.01 Million SEK | 163.319% |
| Duearity AB (publ) | -4.17 Million SEK | -900.479% |
| Dignitana AB (publ) | 58.97 Million SEK | 170.882% |
| Getinge AB (publ) | 13.43 Billion SEK | 100.311% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 16.762% |
| Iconovo AB (publ) | 17.57 Million SEK | 337.802% |
| Integrum AB (publ) | 690.56 Thousand SEK | 6153.041% |
| Luxbright AB (publ) | -2.79 Million SEK | -1394.525% |
| Mentice AB (publ) | 236.38 Million SEK | 117.683% |
| OssDsign AB (publ) | 83.64 Million SEK | 149.973% |
| Paxman AB (publ) | 12.61 Million SEK | 431.273% |
| Promimic AB (publ) | 38.51 Million SEK | 208.529% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 17.64% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 360.647% |
| ScandiDos AB (publ) | 47.55 Million SEK | 187.898% |
| Sectra AB (publ) | 557.55 Million SEK | 107.497% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 138.355% |
| Senzime AB (publ) | 8.33 Million SEK | 601.259% |
| SpectraCure AB (publ) | -9.22 Million SEK | -353.215% |
| Stille AB | 132.17 Million SEK | 131.626% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 102.113% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 110.026% |